Bionor Pharma develops universal influenza vaccine

Washington, 22.11.2011 - Bionor Pharma’s Universal Influenza Vaccine, Vacc-Flu, Targets Regions Shared by all Influenza A Strains; Reduces Serious Flu Symptoms by 25 Percent Over Standard Flu Vaccine in Animal Study.

TREDJE KVARTALS RESULTAT 2011

Bionor Pharma presents on an Influenza congress in US

(Oslo, 31th October, 2011 - Bionor Pharma is invited to present its work on development on an Influenza vaccine on an influenza congress in USA

Adm. dir. tildelt opsjonsordning

20.10.2011 - Adm. dir. Steen Krøyer i Bionor Pharma tildelt opsjonsordning

Mandatory notification of trade

Oslo, 04.10.2011 - Board member of Bionor Pharma ASA, Marianne Furru, has today purchased 140,000 shares

Vacc-4x results presented in Bangkok

Results from Phase IIB Placebo Controlled Study of Bionor’s Vacc-4x Show Excellent Safety Profile and Statistically Significant Viral Load Reduction in Patients with HIV who Suspend Antiretroviral Therapy.

Clinical status for Vacc-4x and Revlimid®

Industry Specialist Steen Krøyer is the new CEO

Oslo, 05.09.2011 - Steen Krøyer appointed as interim CEO of Bionor Pharma ASA

New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)

Oslo - 25.08.11 - Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug

Henrik Lund fratrer som CEO i Bionor Pharma ASA

Oslo, 15.08.2011 - Styret i Bionor Pharma ASA har kommet til enighet med
CEO Henrik Lund om avslutning av arbeidsforholdet.

New Board of Directors elected in Bionor Pharma ASA

Oslo, 25.07.2011 - The shareholders of Bionor Pharma ASA today elected a new Board of Directors at the Extraordinary General Meeting.

Successful therapeutic vaccination with Vacc-4x

Successful therapeutic vaccination of HIV patients with Vacc-4x, Bionor Pharma’s peptide-based therapeutic vaccine for HIV-1 infection

Invitation to the Extraordinary General Meeting 25.07.2011

Oslo, 30.06.2011 - The Extraordinary General Meeting of Bionor Pharma ASA will be held on Monday 25 July 2011, 10:00 a.m. at Hotel Continental in Oslo.

NMA (SLV) approve testing of Vacc-4x using a nasal administration system

Oslo, 16.06.2011 - Oslo University Hospital has received approval to test Bionor Pharma's HIV-vaccine, Vacc-4x, using a nasal administration system

Minutes from the Annual General Meeting of Bionor Pharma ASA

27.05.2011 - Bionor Pharma ASA´s Annual General Meeting was held today. All proposed resolutions in the notice to the meeting were approved by the shareholders

Expert-reviews on universal influenza vaccine

Oslo, 25.05.2011 - Interview with CSO Maja Sommerfelt regarding universal flu vaccine

Bionor Pharma strengthens its IP-platform in the US

Oslo, 20.05.2011 - Bionor Pharma ASA has today received confirmation of submission of patent
applications in the US for its platform technologies.

Bionor Pharma appoints Vice President Business Development

Oslo, 19.05.2011. Bionor Pharma ASA has today appointed Frode Hellesnes as Vice President for Business Development.

Kopi av Årsrapport 2010 for Bionor Pharma ASA

Vacc-4x viewed as the most promising therapeutic vaccine candidate by US AIDS magazine